Three companies combine to form value-based kidney care company estimated at $2.4 billion. Fresenius Health Partners, InterWell Health and Cricket Health will join forces under the InterWell Health brand.
The news is another example of the booming kidney care market. More so, it is an example of the innovations taking place in the market, home care solutions being one of them.
“By holding itself to the highest standards, the new InterWell Health hopes to improve quality of life for patients through reduced hospital admissions and readmissions, slower disease progression, increased referrals and transplant rates, accelerated transition to home dialysis and improved health equity. read the press release.
The company’s goal is to create the “new standard in value-based kidney care in the United States”
But they are not alone. Just last month, value-based home kidney care company Somatus announced that it had raised over $325 million in oversubscribed Series E funding.
Monogram Health – a kidney care management company – recently raised $160 million in its Series B.
Again, these companies are increasingly focusing on providing home care. Retailers such as CVS Health (NYSE: CVS) have also done considerable work on this front.
“Every patient’s situation and needs are unique, and the new organization will deliver game-changing solutions ranging from machine learning to highly personalized engagement that keep patients healthy, at home and out of hospital,” Cricket Health CEO Robert Sepucha said in the press release.
Cricket Health, on the other hand, is a portfolio company of private equity fund Welsh, Carson, Anderson & Stowe (WCAS), which is a major player in senior care. The San Francisco-based Cricket had raised more than $120 million as of August 2021. The company reported last year that 45% of its patients requiring dialysis were started at home, compared to a national benchmark of 11%.
InterWell Health has a nephrology network of more than 1,600 physicians, which positions it to “manage kidney patients in at-risk arrangements with public and private payers across the chronic kidney disease continuum.” “, according to the press release.
Finally, Fresenius Medical Care North America (FMCNA) provides care for people with kidney disease and other chronic conditions. It has a network of dialysis facilities and outpatient cardiac and vascular laboratories, which enable it to provide care to hundreds of thousands of chronically ill people across the continent. Fresenius Health Partners is the value-based healthcare division of FMCNA.
Financial and strategic support came from Valtruis, the WCAS value-based care company that received a $300 million lead last year. Other investors included Oak HC/FT, Cigna Ventures and Blue Shield of California.
“Valtruis has been thrilled with our partnership with Cricket Health to date, and we are excited to help catalyze this game-changing kidney care transaction as we continue to build our value-based care capabilities. and strengthen our strategic relationships across the healthcare ecosystem. said David Caluori, Chairman of the Board of Valtruis, in the statement.
In addition to being valued at $2.4 billion, the combined company will have over $6 billion in medical expenses under management and will also be responsible for over 100,000 lives covered, representing a total addressable market of 170 billion, according to the statement.
One of its goals is to accelerate the growth of the value-based care population for mid- and late-stage chronic kidney disease. By 2025, he hopes to “engage and manage” the care of more than 270,000 Americans living with kidney disease.
“The new InterWell Health will bring together physicians, care management teams and providers,” Bill Valle, CEO of Care Delivery for Fresenius Medical Care, said in the release. “Cricket Health’s predictive analytics and patient engagement platform, combined with InterWell Health’s physician-led clinical approach and Fresenius Health Partners’ experience and expertise in patient-based care on value, will position the organization for accelerated growth.